Table 1

Crude and adjusted RORs for the risk of myopathy associated with the use of antidiabetes agents and lipid-lowering agents, separately and in combination, according to data in the BNPV

Drug-drug interaction of interestExposureCases* (N = 3,252)Noncases (N = 187,035)Crude ROR (95% CI)Adjusted ROR (95% CI)
DPP-4is and statinsNo DPP-4is, no statins2,452174,582refref
DPP-4is, no statins231,0991.5 (1.0–2.3)2.1 (1.3–3.3)
Statins, no DPP-4is75810,8505.0 (4.6–5.4)6.2 (5.7–6.8)
DPP-4is and statins195042.7 (1.7–4.3)4.5 (2.7–7.6)
DPP-4is and fibratesNo DPP-4is, no fibrates3,140184,153refref
DPP-4is, no fibrates391,5531.5 (1.1–2.1)1.6 (1.1–2.4)
Fibrates, no DPP-4is701,2723.2 (2.5–4.1)4.4 (3.4–5.6)
DPP-4is and fibrates3573.1 (1.0–9.9)6.3 (1.9–20.7)
nAOs and statinsNo nAOs, no statins2,416169,809refref
nAOs, no statins595,8720.7 (0.5–0.9)0.6 (0.4–0.8)
Statins, no nAOs6979,0955.3 (5.0–5.9)6.3 (5.7–6.9)
nAOs and statins802,2592.5 (2.0–3.1)2.7 (2.1–3.5)
nAOs and fibratesNo nAOs, no fibrates3,048177,837refref
nAOs, no fibrates1317,8691.0 (0.8–1.2)0.5 (0.4–0.6)
Fibrates, no nAOs651,0673.6 (2.8–4.6)4.5 (3.5–5.5)
nAOs and fibrates82621.8 (0.9–3.6)1.8 (0.9–3.8)
  • DPP-4is, DPP-4 inhibitors; nAOs, noninsulin antidiabetes agents other than DPP-4is.

  • * Cases of myopathy.

  • Adjusted for age and sex, statins or fibrates depending on the lipid-lowering exposure of interest, and DPP-4is or nAOs depending on the glucose-lowering exposure of interest.